4000 recovered COVID-19 patients in Daegu are willed to donate blood plasma
Online PR News – 16-July-2020 – Essen, 16.07.2020 – 4000 recovered COVID-19 patients in Daegu are willed to donate blood plasma
South Korea has massively contributed to the global research efforts for an effective and safe treatment of COVID-19. From the nationwide amount of 12.065 rehabilitated patients, a total of 4000 patients are willed to donate their blood plasma.
Just recently a research team of the University of Hong Kong published promising results:
The blood plasma of a recovered patient – so called convalescent plasma - can be implemented to eliminate 99% of the disease in an ill patient. After a blood plasma transfusion, ten out of ten infected participants survived. The virus count and symptoms both decreased significantly quicker, juxtaposed to a peer group, in which the participants of the study had not received a plasma transfusion, which resulted in the death of three participants. Research and development of this new therapy should minimize the deaths connected to this disease.
According to current data of the Korean Center for Disease Control and Prevention (KCDC), the number of severe cases has dropped from 42 to 27. Whereas 15 of which showed no signs of improvement, three cases showed a deteriorated condition and nine cases showed improvement.
“It is not sure, if the improvements originate from medicine, the treatment of symptoms or the immune system of the patients”, stated the department manager in charge, Mr. Gwon Junuk.
In collaboration with South Korean health authorities, a plan was drawn up for the realization of the donation and within this week, 500 donors will give their blood plasma.
The voluntary donors belong to a religious group called Shincheonji Church of Jesus, which fell victim to the first major outbreak outside of China in February 2020. Due to the pandemic and the worldwide lack of donors, the value of blood plasma rose sharply. Therefore, a donation consisting of 4.000 people donating 500ml blood each, accounts for a value in the high double-digit million-dollar range.
An official of a biopharmaceutical company in South Korea, Green Cross Pharma, explained, “It is difficult to accelera¬te developing a medicine for COVID-19 with only 200 recovered patients who expressed their will to donate blood. The massive donation from the recovered patients in Daegu, will compensate for lack of blood for research.”
Overall, the measures of South Korea taken to contain the virus are exemplary on an international scale. Now the country can also be a pioneer in developing a cure for COVID-19.
With almost 200.000 confirmed cases of COVID-19, Germany is one of the most affected countries by the pandemic. And here too, those who have recovered are advised to donate blood plasma by health organizations.